Pharma & Healthcare
Global Non-prescription Drugs Market Research Report 2025
- Sep 09, 25
- ID: 497307
- Pages: 100
- Figures: 98
- Views: 5
This report aims to provide a comprehensive presentation of the global market for Non-prescription Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-prescription Drugs.
The Non-prescription Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-prescription Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-prescription Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
AbbVie
Takeda
Boehringer Ingelheim
Takeda
Segment by Type
Brand Drugs
Generic Drug
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-prescription Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Non-prescription Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-prescription Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-prescription Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
AbbVie
Takeda
Boehringer Ingelheim
Takeda
Segment by Type
Brand Drugs
Generic Drug
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-prescription Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-prescription Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Brand Drugs
1.2.3 Generic Drug
1.3 Market by Application
1.3.1 Global Non-prescription Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-prescription Drugs Market Perspective (2020-2031)
2.2 Global Non-prescription Drugs Growth Trends by Region
2.2.1 Global Non-prescription Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Non-prescription Drugs Historic Market Size by Region (2020-2025)
2.2.3 Non-prescription Drugs Forecasted Market Size by Region (2026-2031)
2.3 Non-prescription Drugs Market Dynamics
2.3.1 Non-prescription Drugs Industry Trends
2.3.2 Non-prescription Drugs Market Drivers
2.3.3 Non-prescription Drugs Market Challenges
2.3.4 Non-prescription Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-prescription Drugs Players by Revenue
3.1.1 Global Top Non-prescription Drugs Players by Revenue (2020-2025)
3.1.2 Global Non-prescription Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Non-prescription Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Non-prescription Drugs Revenue
3.4 Global Non-prescription Drugs Market Concentration Ratio
3.4.1 Global Non-prescription Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-prescription Drugs Revenue in 2024
3.5 Global Key Players of Non-prescription Drugs Head office and Area Served
3.6 Global Key Players of Non-prescription Drugs, Product and Application
3.7 Global Key Players of Non-prescription Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-prescription Drugs Breakdown Data by Type
4.1 Global Non-prescription Drugs Historic Market Size by Type (2020-2025)
4.2 Global Non-prescription Drugs Forecasted Market Size by Type (2026-2031)
5 Non-prescription Drugs Breakdown Data by Application
5.1 Global Non-prescription Drugs Historic Market Size by Application (2020-2025)
5.2 Global Non-prescription Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Non-prescription Drugs Market Size (2020-2031)
6.2 North America Non-prescription Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Non-prescription Drugs Market Size by Country (2020-2025)
6.4 North America Non-prescription Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-prescription Drugs Market Size (2020-2031)
7.2 Europe Non-prescription Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Non-prescription Drugs Market Size by Country (2020-2025)
7.4 Europe Non-prescription Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-prescription Drugs Market Size (2020-2031)
8.2 Asia-Pacific Non-prescription Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Non-prescription Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Non-prescription Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-prescription Drugs Market Size (2020-2031)
9.2 Latin America Non-prescription Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Non-prescription Drugs Market Size by Country (2020-2025)
9.4 Latin America Non-prescription Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-prescription Drugs Market Size (2020-2031)
10.2 Middle East & Africa Non-prescription Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Non-prescription Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Non-prescription Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Non-prescription Drugs Introduction
11.1.4 Pfizer Revenue in Non-prescription Drugs Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Non-prescription Drugs Introduction
11.2.4 Roche Revenue in Non-prescription Drugs Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Non-prescription Drugs Introduction
11.3.4 Sanofi Revenue in Non-prescription Drugs Business (2020-2025)
11.3.5 Sanofi Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Non-prescription Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Non-prescription Drugs Business (2020-2025)
11.4.5 Johnson & Johnson Recent Development
11.5 Merck & Co. (MSD)
11.5.1 Merck & Co. (MSD) Company Details
11.5.2 Merck & Co. (MSD) Business Overview
11.5.3 Merck & Co. (MSD) Non-prescription Drugs Introduction
11.5.4 Merck & Co. (MSD) Revenue in Non-prescription Drugs Business (2020-2025)
11.5.5 Merck & Co. (MSD) Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-prescription Drugs Introduction
11.6.4 Novartis Revenue in Non-prescription Drugs Business (2020-2025)
11.6.5 Novartis Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Details
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Non-prescription Drugs Introduction
11.7.4 AbbVie Revenue in Non-prescription Drugs Business (2020-2025)
11.7.5 AbbVie Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Non-prescription Drugs Introduction
11.8.4 Gilead Sciences Revenue in Non-prescription Drugs Business (2020-2025)
11.8.5 Gilead Sciences Recent Development
11.9 GlaxoSmithKline (GSK)
11.9.1 GlaxoSmithKline (GSK) Company Details
11.9.2 GlaxoSmithKline (GSK) Business Overview
11.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Introduction
11.9.4 GlaxoSmithKline (GSK) Revenue in Non-prescription Drugs Business (2020-2025)
11.9.5 GlaxoSmithKline (GSK) Recent Development
11.10 Amgen
11.10.1 Amgen Company Details
11.10.2 Amgen Business Overview
11.10.3 Amgen Non-prescription Drugs Introduction
11.10.4 Amgen Revenue in Non-prescription Drugs Business (2020-2025)
11.10.5 Amgen Recent Development
11.11 AstraZeneca
11.11.1 AstraZeneca Company Details
11.11.2 AstraZeneca Business Overview
11.11.3 AstraZeneca Non-prescription Drugs Introduction
11.11.4 AstraZeneca Revenue in Non-prescription Drugs Business (2020-2025)
11.11.5 AstraZeneca Recent Development
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Company Details
11.12.2 Bristol-Myers Squibb Business Overview
11.12.3 Bristol-Myers Squibb Non-prescription Drugs Introduction
11.12.4 Bristol-Myers Squibb Revenue in Non-prescription Drugs Business (2020-2025)
11.12.5 Bristol-Myers Squibb Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Details
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Non-prescription Drugs Introduction
11.13.4 Eli Lilly Revenue in Non-prescription Drugs Business (2020-2025)
11.13.5 Eli Lilly Recent Development
11.14 Teva
11.14.1 Teva Company Details
11.14.2 Teva Business Overview
11.14.3 Teva Non-prescription Drugs Introduction
11.14.4 Teva Revenue in Non-prescription Drugs Business (2020-2025)
11.14.5 Teva Recent Development
11.15 Bayer
11.15.1 Bayer Company Details
11.15.2 Bayer Business Overview
11.15.3 Bayer Non-prescription Drugs Introduction
11.15.4 Bayer Revenue in Non-prescription Drugs Business (2020-2025)
11.15.5 Bayer Recent Development
11.16 Novo Nordisk
11.16.1 Novo Nordisk Company Details
11.16.2 Novo Nordisk Business Overview
11.16.3 Novo Nordisk Non-prescription Drugs Introduction
11.16.4 Novo Nordisk Revenue in Non-prescription Drugs Business (2020-2025)
11.16.5 Novo Nordisk Recent Development
11.17 AbbVie
11.17.1 AbbVie Company Details
11.17.2 AbbVie Business Overview
11.17.3 AbbVie Non-prescription Drugs Introduction
11.17.4 AbbVie Revenue in Non-prescription Drugs Business (2020-2025)
11.17.5 AbbVie Recent Development
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Non-prescription Drugs Introduction
11.18.4 Takeda Revenue in Non-prescription Drugs Business (2020-2025)
11.18.5 Takeda Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Details
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-prescription Drugs Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-prescription Drugs Business (2020-2025)
11.19.5 Boehringer Ingelheim Recent Development
11.20 Takeda
11.20.1 Takeda Company Details
11.20.2 Takeda Business Overview
11.20.3 Takeda Non-prescription Drugs Introduction
11.20.4 Takeda Revenue in Non-prescription Drugs Business (2020-2025)
11.20.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-prescription Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Brand Drugs
1.2.3 Generic Drug
1.3 Market by Application
1.3.1 Global Non-prescription Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-prescription Drugs Market Perspective (2020-2031)
2.2 Global Non-prescription Drugs Growth Trends by Region
2.2.1 Global Non-prescription Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Non-prescription Drugs Historic Market Size by Region (2020-2025)
2.2.3 Non-prescription Drugs Forecasted Market Size by Region (2026-2031)
2.3 Non-prescription Drugs Market Dynamics
2.3.1 Non-prescription Drugs Industry Trends
2.3.2 Non-prescription Drugs Market Drivers
2.3.3 Non-prescription Drugs Market Challenges
2.3.4 Non-prescription Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-prescription Drugs Players by Revenue
3.1.1 Global Top Non-prescription Drugs Players by Revenue (2020-2025)
3.1.2 Global Non-prescription Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Non-prescription Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Non-prescription Drugs Revenue
3.4 Global Non-prescription Drugs Market Concentration Ratio
3.4.1 Global Non-prescription Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-prescription Drugs Revenue in 2024
3.5 Global Key Players of Non-prescription Drugs Head office and Area Served
3.6 Global Key Players of Non-prescription Drugs, Product and Application
3.7 Global Key Players of Non-prescription Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-prescription Drugs Breakdown Data by Type
4.1 Global Non-prescription Drugs Historic Market Size by Type (2020-2025)
4.2 Global Non-prescription Drugs Forecasted Market Size by Type (2026-2031)
5 Non-prescription Drugs Breakdown Data by Application
5.1 Global Non-prescription Drugs Historic Market Size by Application (2020-2025)
5.2 Global Non-prescription Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Non-prescription Drugs Market Size (2020-2031)
6.2 North America Non-prescription Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Non-prescription Drugs Market Size by Country (2020-2025)
6.4 North America Non-prescription Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-prescription Drugs Market Size (2020-2031)
7.2 Europe Non-prescription Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Non-prescription Drugs Market Size by Country (2020-2025)
7.4 Europe Non-prescription Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-prescription Drugs Market Size (2020-2031)
8.2 Asia-Pacific Non-prescription Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Non-prescription Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Non-prescription Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-prescription Drugs Market Size (2020-2031)
9.2 Latin America Non-prescription Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Non-prescription Drugs Market Size by Country (2020-2025)
9.4 Latin America Non-prescription Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-prescription Drugs Market Size (2020-2031)
10.2 Middle East & Africa Non-prescription Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Non-prescription Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Non-prescription Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Non-prescription Drugs Introduction
11.1.4 Pfizer Revenue in Non-prescription Drugs Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Non-prescription Drugs Introduction
11.2.4 Roche Revenue in Non-prescription Drugs Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Non-prescription Drugs Introduction
11.3.4 Sanofi Revenue in Non-prescription Drugs Business (2020-2025)
11.3.5 Sanofi Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Non-prescription Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Non-prescription Drugs Business (2020-2025)
11.4.5 Johnson & Johnson Recent Development
11.5 Merck & Co. (MSD)
11.5.1 Merck & Co. (MSD) Company Details
11.5.2 Merck & Co. (MSD) Business Overview
11.5.3 Merck & Co. (MSD) Non-prescription Drugs Introduction
11.5.4 Merck & Co. (MSD) Revenue in Non-prescription Drugs Business (2020-2025)
11.5.5 Merck & Co. (MSD) Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-prescription Drugs Introduction
11.6.4 Novartis Revenue in Non-prescription Drugs Business (2020-2025)
11.6.5 Novartis Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Details
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Non-prescription Drugs Introduction
11.7.4 AbbVie Revenue in Non-prescription Drugs Business (2020-2025)
11.7.5 AbbVie Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Non-prescription Drugs Introduction
11.8.4 Gilead Sciences Revenue in Non-prescription Drugs Business (2020-2025)
11.8.5 Gilead Sciences Recent Development
11.9 GlaxoSmithKline (GSK)
11.9.1 GlaxoSmithKline (GSK) Company Details
11.9.2 GlaxoSmithKline (GSK) Business Overview
11.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Introduction
11.9.4 GlaxoSmithKline (GSK) Revenue in Non-prescription Drugs Business (2020-2025)
11.9.5 GlaxoSmithKline (GSK) Recent Development
11.10 Amgen
11.10.1 Amgen Company Details
11.10.2 Amgen Business Overview
11.10.3 Amgen Non-prescription Drugs Introduction
11.10.4 Amgen Revenue in Non-prescription Drugs Business (2020-2025)
11.10.5 Amgen Recent Development
11.11 AstraZeneca
11.11.1 AstraZeneca Company Details
11.11.2 AstraZeneca Business Overview
11.11.3 AstraZeneca Non-prescription Drugs Introduction
11.11.4 AstraZeneca Revenue in Non-prescription Drugs Business (2020-2025)
11.11.5 AstraZeneca Recent Development
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Company Details
11.12.2 Bristol-Myers Squibb Business Overview
11.12.3 Bristol-Myers Squibb Non-prescription Drugs Introduction
11.12.4 Bristol-Myers Squibb Revenue in Non-prescription Drugs Business (2020-2025)
11.12.5 Bristol-Myers Squibb Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Details
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Non-prescription Drugs Introduction
11.13.4 Eli Lilly Revenue in Non-prescription Drugs Business (2020-2025)
11.13.5 Eli Lilly Recent Development
11.14 Teva
11.14.1 Teva Company Details
11.14.2 Teva Business Overview
11.14.3 Teva Non-prescription Drugs Introduction
11.14.4 Teva Revenue in Non-prescription Drugs Business (2020-2025)
11.14.5 Teva Recent Development
11.15 Bayer
11.15.1 Bayer Company Details
11.15.2 Bayer Business Overview
11.15.3 Bayer Non-prescription Drugs Introduction
11.15.4 Bayer Revenue in Non-prescription Drugs Business (2020-2025)
11.15.5 Bayer Recent Development
11.16 Novo Nordisk
11.16.1 Novo Nordisk Company Details
11.16.2 Novo Nordisk Business Overview
11.16.3 Novo Nordisk Non-prescription Drugs Introduction
11.16.4 Novo Nordisk Revenue in Non-prescription Drugs Business (2020-2025)
11.16.5 Novo Nordisk Recent Development
11.17 AbbVie
11.17.1 AbbVie Company Details
11.17.2 AbbVie Business Overview
11.17.3 AbbVie Non-prescription Drugs Introduction
11.17.4 AbbVie Revenue in Non-prescription Drugs Business (2020-2025)
11.17.5 AbbVie Recent Development
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Non-prescription Drugs Introduction
11.18.4 Takeda Revenue in Non-prescription Drugs Business (2020-2025)
11.18.5 Takeda Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Details
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-prescription Drugs Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-prescription Drugs Business (2020-2025)
11.19.5 Boehringer Ingelheim Recent Development
11.20 Takeda
11.20.1 Takeda Company Details
11.20.2 Takeda Business Overview
11.20.3 Takeda Non-prescription Drugs Introduction
11.20.4 Takeda Revenue in Non-prescription Drugs Business (2020-2025)
11.20.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Non-prescription Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Brand Drugs
Table 3. Key Players of Generic Drug
Table 4. Global Non-prescription Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Non-prescription Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Non-prescription Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Non-prescription Drugs Market Share by Region (2020-2025)
Table 8. Global Non-prescription Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Non-prescription Drugs Market Share by Region (2026-2031)
Table 10. Non-prescription Drugs Market Trends
Table 11. Non-prescription Drugs Market Drivers
Table 12. Non-prescription Drugs Market Challenges
Table 13. Non-prescription Drugs Market Restraints
Table 14. Global Non-prescription Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Non-prescription Drugs Market Share by Players (2020-2025)
Table 16. Global Top Non-prescription Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-prescription Drugs as of 2024)
Table 17. Ranking of Global Top Non-prescription Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Non-prescription Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Non-prescription Drugs, Headquarters and Area Served
Table 20. Global Key Players of Non-prescription Drugs, Product and Application
Table 21. Global Key Players of Non-prescription Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-prescription Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Non-prescription Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Non-prescription Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Non-prescription Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Non-prescription Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Non-prescription Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Non-prescription Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Non-prescription Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Non-prescription Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Non-prescription Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Non-prescription Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Non-prescription Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Non-prescription Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Non-prescription Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Non-prescription Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Non-prescription Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Non-prescription Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Non-prescription Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Non-prescription Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Non-prescription Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Non-prescription Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Non-prescription Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Non-prescription Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Pfizer Company Details
Table 47. Pfizer Business Overview
Table 48. Pfizer Non-prescription Drugs Product
Table 49. Pfizer Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. Roche Company Details
Table 52. Roche Business Overview
Table 53. Roche Non-prescription Drugs Product
Table 54. Roche Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 55. Roche Recent Development
Table 56. Sanofi Company Details
Table 57. Sanofi Business Overview
Table 58. Sanofi Non-prescription Drugs Product
Table 59. Sanofi Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 60. Sanofi Recent Development
Table 61. Johnson & Johnson Company Details
Table 62. Johnson & Johnson Business Overview
Table 63. Johnson & Johnson Non-prescription Drugs Product
Table 64. Johnson & Johnson Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 65. Johnson & Johnson Recent Development
Table 66. Merck & Co. (MSD) Company Details
Table 67. Merck & Co. (MSD) Business Overview
Table 68. Merck & Co. (MSD) Non-prescription Drugs Product
Table 69. Merck & Co. (MSD) Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 70. Merck & Co. (MSD) Recent Development
Table 71. Novartis Company Details
Table 72. Novartis Business Overview
Table 73. Novartis Non-prescription Drugs Product
Table 74. Novartis Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. AbbVie Company Details
Table 77. AbbVie Business Overview
Table 78. AbbVie Non-prescription Drugs Product
Table 79. AbbVie Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 80. AbbVie Recent Development
Table 81. Gilead Sciences Company Details
Table 82. Gilead Sciences Business Overview
Table 83. Gilead Sciences Non-prescription Drugs Product
Table 84. Gilead Sciences Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 85. Gilead Sciences Recent Development
Table 86. GlaxoSmithKline (GSK) Company Details
Table 87. GlaxoSmithKline (GSK) Business Overview
Table 88. GlaxoSmithKline (GSK) Non-prescription Drugs Product
Table 89. GlaxoSmithKline (GSK) Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 90. GlaxoSmithKline (GSK) Recent Development
Table 91. Amgen Company Details
Table 92. Amgen Business Overview
Table 93. Amgen Non-prescription Drugs Product
Table 94. Amgen Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 95. Amgen Recent Development
Table 96. AstraZeneca Company Details
Table 97. AstraZeneca Business Overview
Table 98. AstraZeneca Non-prescription Drugs Product
Table 99. AstraZeneca Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 100. AstraZeneca Recent Development
Table 101. Bristol-Myers Squibb Company Details
Table 102. Bristol-Myers Squibb Business Overview
Table 103. Bristol-Myers Squibb Non-prescription Drugs Product
Table 104. Bristol-Myers Squibb Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 105. Bristol-Myers Squibb Recent Development
Table 106. Eli Lilly Company Details
Table 107. Eli Lilly Business Overview
Table 108. Eli Lilly Non-prescription Drugs Product
Table 109. Eli Lilly Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 110. Eli Lilly Recent Development
Table 111. Teva Company Details
Table 112. Teva Business Overview
Table 113. Teva Non-prescription Drugs Product
Table 114. Teva Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 115. Teva Recent Development
Table 116. Bayer Company Details
Table 117. Bayer Business Overview
Table 118. Bayer Non-prescription Drugs Product
Table 119. Bayer Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 120. Bayer Recent Development
Table 121. Novo Nordisk Company Details
Table 122. Novo Nordisk Business Overview
Table 123. Novo Nordisk Non-prescription Drugs Product
Table 124. Novo Nordisk Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 125. Novo Nordisk Recent Development
Table 126. AbbVie Company Details
Table 127. AbbVie Business Overview
Table 128. AbbVie Non-prescription Drugs Product
Table 129. AbbVie Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 130. AbbVie Recent Development
Table 131. Takeda Company Details
Table 132. Takeda Business Overview
Table 133. Takeda Non-prescription Drugs Product
Table 134. Takeda Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 135. Takeda Recent Development
Table 136. Boehringer Ingelheim Company Details
Table 137. Boehringer Ingelheim Business Overview
Table 138. Boehringer Ingelheim Non-prescription Drugs Product
Table 139. Boehringer Ingelheim Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 140. Boehringer Ingelheim Recent Development
Table 141. Takeda Company Details
Table 142. Takeda Business Overview
Table 143. Takeda Non-prescription Drugs Product
Table 144. Takeda Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 145. Takeda Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
Table 149. Authors List of This Report
List of Figures
Figure 1. Non-prescription Drugs Picture
Figure 2. Global Non-prescription Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Non-prescription Drugs Market Share by Type: 2024 VS 2031
Figure 4. Brand Drugs Features
Figure 5. Generic Drug Features
Figure 6. Global Non-prescription Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Non-prescription Drugs Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Other Case Studies
Figure 11. Non-prescription Drugs Report Years Considered
Figure 12. Global Non-prescription Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Non-prescription Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Non-prescription Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Non-prescription Drugs Market Share by Players in 2024
Figure 16. Global Top Non-prescription Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-prescription Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Non-prescription Drugs Revenue in 2024
Figure 18. North America Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Non-prescription Drugs Market Share by Country (2020-2031)
Figure 20. United States Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Non-prescription Drugs Market Share by Country (2020-2031)
Figure 24. Germany Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Non-prescription Drugs Market Share by Region (2020-2031)
Figure 32. China Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Non-prescription Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Non-prescription Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 48. Roche Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 49. Sanofi Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 50. Johnson & Johnson Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 51. Merck & Co. (MSD) Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 52. Novartis Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 53. AbbVie Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 54. Gilead Sciences Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 55. GlaxoSmithKline (GSK) Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 56. Amgen Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 57. AstraZeneca Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 59. Eli Lilly Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 60. Teva Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 61. Bayer Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 62. Novo Nordisk Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 63. AbbVie Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 64. Takeda Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 65. Boehringer Ingelheim Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 66. Takeda Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Table 1. Global Non-prescription Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Brand Drugs
Table 3. Key Players of Generic Drug
Table 4. Global Non-prescription Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Non-prescription Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Non-prescription Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Non-prescription Drugs Market Share by Region (2020-2025)
Table 8. Global Non-prescription Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Non-prescription Drugs Market Share by Region (2026-2031)
Table 10. Non-prescription Drugs Market Trends
Table 11. Non-prescription Drugs Market Drivers
Table 12. Non-prescription Drugs Market Challenges
Table 13. Non-prescription Drugs Market Restraints
Table 14. Global Non-prescription Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Non-prescription Drugs Market Share by Players (2020-2025)
Table 16. Global Top Non-prescription Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-prescription Drugs as of 2024)
Table 17. Ranking of Global Top Non-prescription Drugs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Non-prescription Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Non-prescription Drugs, Headquarters and Area Served
Table 20. Global Key Players of Non-prescription Drugs, Product and Application
Table 21. Global Key Players of Non-prescription Drugs, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-prescription Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Non-prescription Drugs Revenue Market Share by Type (2020-2025)
Table 25. Global Non-prescription Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Non-prescription Drugs Revenue Market Share by Type (2026-2031)
Table 27. Global Non-prescription Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Non-prescription Drugs Revenue Market Share by Application (2020-2025)
Table 29. Global Non-prescription Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Non-prescription Drugs Revenue Market Share by Application (2026-2031)
Table 31. North America Non-prescription Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Non-prescription Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Non-prescription Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Non-prescription Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Non-prescription Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Non-prescription Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Non-prescription Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Non-prescription Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Non-prescription Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Non-prescription Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Non-prescription Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Non-prescription Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Non-prescription Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Non-prescription Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Non-prescription Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Pfizer Company Details
Table 47. Pfizer Business Overview
Table 48. Pfizer Non-prescription Drugs Product
Table 49. Pfizer Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. Roche Company Details
Table 52. Roche Business Overview
Table 53. Roche Non-prescription Drugs Product
Table 54. Roche Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 55. Roche Recent Development
Table 56. Sanofi Company Details
Table 57. Sanofi Business Overview
Table 58. Sanofi Non-prescription Drugs Product
Table 59. Sanofi Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 60. Sanofi Recent Development
Table 61. Johnson & Johnson Company Details
Table 62. Johnson & Johnson Business Overview
Table 63. Johnson & Johnson Non-prescription Drugs Product
Table 64. Johnson & Johnson Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 65. Johnson & Johnson Recent Development
Table 66. Merck & Co. (MSD) Company Details
Table 67. Merck & Co. (MSD) Business Overview
Table 68. Merck & Co. (MSD) Non-prescription Drugs Product
Table 69. Merck & Co. (MSD) Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 70. Merck & Co. (MSD) Recent Development
Table 71. Novartis Company Details
Table 72. Novartis Business Overview
Table 73. Novartis Non-prescription Drugs Product
Table 74. Novartis Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. AbbVie Company Details
Table 77. AbbVie Business Overview
Table 78. AbbVie Non-prescription Drugs Product
Table 79. AbbVie Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 80. AbbVie Recent Development
Table 81. Gilead Sciences Company Details
Table 82. Gilead Sciences Business Overview
Table 83. Gilead Sciences Non-prescription Drugs Product
Table 84. Gilead Sciences Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 85. Gilead Sciences Recent Development
Table 86. GlaxoSmithKline (GSK) Company Details
Table 87. GlaxoSmithKline (GSK) Business Overview
Table 88. GlaxoSmithKline (GSK) Non-prescription Drugs Product
Table 89. GlaxoSmithKline (GSK) Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 90. GlaxoSmithKline (GSK) Recent Development
Table 91. Amgen Company Details
Table 92. Amgen Business Overview
Table 93. Amgen Non-prescription Drugs Product
Table 94. Amgen Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 95. Amgen Recent Development
Table 96. AstraZeneca Company Details
Table 97. AstraZeneca Business Overview
Table 98. AstraZeneca Non-prescription Drugs Product
Table 99. AstraZeneca Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 100. AstraZeneca Recent Development
Table 101. Bristol-Myers Squibb Company Details
Table 102. Bristol-Myers Squibb Business Overview
Table 103. Bristol-Myers Squibb Non-prescription Drugs Product
Table 104. Bristol-Myers Squibb Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 105. Bristol-Myers Squibb Recent Development
Table 106. Eli Lilly Company Details
Table 107. Eli Lilly Business Overview
Table 108. Eli Lilly Non-prescription Drugs Product
Table 109. Eli Lilly Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 110. Eli Lilly Recent Development
Table 111. Teva Company Details
Table 112. Teva Business Overview
Table 113. Teva Non-prescription Drugs Product
Table 114. Teva Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 115. Teva Recent Development
Table 116. Bayer Company Details
Table 117. Bayer Business Overview
Table 118. Bayer Non-prescription Drugs Product
Table 119. Bayer Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 120. Bayer Recent Development
Table 121. Novo Nordisk Company Details
Table 122. Novo Nordisk Business Overview
Table 123. Novo Nordisk Non-prescription Drugs Product
Table 124. Novo Nordisk Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 125. Novo Nordisk Recent Development
Table 126. AbbVie Company Details
Table 127. AbbVie Business Overview
Table 128. AbbVie Non-prescription Drugs Product
Table 129. AbbVie Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 130. AbbVie Recent Development
Table 131. Takeda Company Details
Table 132. Takeda Business Overview
Table 133. Takeda Non-prescription Drugs Product
Table 134. Takeda Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 135. Takeda Recent Development
Table 136. Boehringer Ingelheim Company Details
Table 137. Boehringer Ingelheim Business Overview
Table 138. Boehringer Ingelheim Non-prescription Drugs Product
Table 139. Boehringer Ingelheim Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 140. Boehringer Ingelheim Recent Development
Table 141. Takeda Company Details
Table 142. Takeda Business Overview
Table 143. Takeda Non-prescription Drugs Product
Table 144. Takeda Revenue in Non-prescription Drugs Business (2020-2025) & (US$ Million)
Table 145. Takeda Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
Table 149. Authors List of This Report
List of Figures
Figure 1. Non-prescription Drugs Picture
Figure 2. Global Non-prescription Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Non-prescription Drugs Market Share by Type: 2024 VS 2031
Figure 4. Brand Drugs Features
Figure 5. Generic Drug Features
Figure 6. Global Non-prescription Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Non-prescription Drugs Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Other Case Studies
Figure 11. Non-prescription Drugs Report Years Considered
Figure 12. Global Non-prescription Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Non-prescription Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Non-prescription Drugs Market Share by Region: 2024 VS 2031
Figure 15. Global Non-prescription Drugs Market Share by Players in 2024
Figure 16. Global Top Non-prescription Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-prescription Drugs as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Non-prescription Drugs Revenue in 2024
Figure 18. North America Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Non-prescription Drugs Market Share by Country (2020-2031)
Figure 20. United States Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Non-prescription Drugs Market Share by Country (2020-2031)
Figure 24. Germany Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Non-prescription Drugs Market Share by Region (2020-2031)
Figure 32. China Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Non-prescription Drugs Market Share by Country (2020-2031)
Figure 40. Mexico Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Non-prescription Drugs Market Share by Country (2020-2031)
Figure 44. Turkey Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Non-prescription Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Pfizer Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 48. Roche Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 49. Sanofi Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 50. Johnson & Johnson Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 51. Merck & Co. (MSD) Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 52. Novartis Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 53. AbbVie Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 54. Gilead Sciences Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 55. GlaxoSmithKline (GSK) Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 56. Amgen Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 57. AstraZeneca Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 59. Eli Lilly Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 60. Teva Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 61. Bayer Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 62. Novo Nordisk Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 63. AbbVie Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 64. Takeda Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 65. Boehringer Ingelheim Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 66. Takeda Revenue Growth Rate in Non-prescription Drugs Business (2020-2025)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Outdoor Shed Market Research Report 2025
Sep 09, 25
Global Residential Outdoor Cabinet Market Research Report 2025
Sep 09, 25
Global Outdoor Storage Cabinet Market Research Report 2025
Sep 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232